best digital health platforms with glp-1 coverage options What's next for innovation: A primer on the race reshaping pharma and chronic disease care What You Need To Know
Description
Molecules above 800 to 1,000 Daltons transfer poorly
Dealing with limited overlap in estimation of average treatment effects
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: A randomised, placebo-controlled and active comparator-controlled phase 2 trial
Steps to take right now to protect your claim Even if you have not decided whether to file a lawsuit, taking certain steps now protects your options for the future
28,29 Although highly effective, 30 patients must administer injections of exenatide multiple times a day leading to low patient compliance
